3D PRINTING AND BIOPRINTING: TODAY AND TOMORROW IN THE ORTHOPEDIC FIELD – HORIZON 2030 - 2050

Prof. Dr. Lucian Reclaru [1], Prof. Dr. Dan Gheorghe Malaescu[2], Lecturer Ioan Dogariu[2] Lecturer Dr. Gabriel Buciu [2]

1 Independent scientific consultant, Biomaterials and Medical Devices, Switzerland
2 Titu Maiorescu University Faculty of General Health Care, Targu Jiu, Romania
DOI: https://doi.org/10.66793/titum19proceeding10

Abstract: *3D printing, or additive manufacturing, profoundly transforms the orthopedic field by allowing the design and production of custom implants from patient-specific digital data. Unlike CAD/CAM, which is based on subtractive machining, 3D printing relies on the addition of successive layers of material, opening the way to porous, light and biomimetic structures that promote osseointegration. Born in the 1980s with the SLS laser CO in Austin (Texas), this technology has extended to metals, ceramics and polymers. Today, bio-printing adds a biological dimension, integrating cells and matrices to manufacture tissues and living grafts. By 2030-2050, the convergence between engineering, artificial intelligence and biology will allow the production of personalized organs and living hybrid implants, marking the advent of printed and customized regenerative medicine.*

1. Introduction

For more than two decades, three-dimensional printing (3D printing) – also called additive manufacturing – has established itself as a disruptive technology in many industrial fields. In orthopedics, it is no longer limited to the production of prototypes: it redefines the design, manufacturing and customization of implants and medical devices.

From computer-aided design (CAD) to computer-aided manufacturing (CAM), to bioprinting of living tissues, the advances are dazzling. 3D printing marks, according to several observers, the beginning of a third industrial revolution, following the mass production of the 20th century. By 2030-2050, it should be fully integrated into surgical practice and regenerative medicine.

2. Clarify the difference between CAD/CAM and 3D Printing

In the medical field, and particularly in orthopedics, the terms CAD/CAM (Computer-Aided Design / Computer-Aided Manufacturing) and 3D Printing (Additive Manufacturing) are often used interchangeably, although they refer to two fundamentally different approaches. This confusion is frequent, as the two technologies share the same numerical basis – computer-aided design – but deeply diverge in their manufacturing principles.

The CAD/CAM system is based on a subtractive process: a part is machined from a raw block (metal, ceramic or polymer) by milling, turning or grinding. This is a high-precision process, perfectly suited to hard materials (CoCr, zirconia, titanium). On the other hand, it generates a significant loss of material, requires costly mechanical tooling and offers limited geometric flexibility (Fig.1).

3D printing, or additive manufacturing, proceeds in the opposite way: the part is built layer by layer from a powder, a filament or a resin (Fig.2). This mode of production allows complex geometries, porous internal structures and patient-specific customization impossible by conventional machining. On the other hand, it presents technical challenges: residual stresses, surface roughness, internal porosity and still incomplete validation of long-term mechanical properties **Table 1**

Table 1 Comparative Aspect CAD/CAM -3D Printing

Comparative aspect	CAD/CAM (subtractive)	3D Printing (additive)
Principle	Material removal (machining)	Successive layer deposition
Typical materials	Metal or ceramic blocks	Powders, polymers, metals, ceramic
Dimensional accuracy	Excellent (µm)	Good to medium depending on the process
Freedom of design	Very high	Limited design freedom (internal structures, porosity)
Material loss	High	Minimal
Production speed	Fast for standard series	Slower, suitable for single piece
Typical applications	Dental crowns, standard prostheses, milled implants	Custom implants, porous bone structures, biological prototypes

Thus, CAD/CAM remains essential for devices requiring high geometric precision and hard materials, while 3D printing opens the way to biological and structural customization of implants, particularly in regenerative orthopaedics.

3. 3D printing technologies and historical evolution

3D printing is based on the superposition of successive layers of material from a digital model (CAD file). The technologies according to the materials used and the clinical needs are:

- Selective laser sintering (SLS) and selective laser melting (SLM): mainly for metal alloys (titanium, cobalt-chromium, steels, aluminum).
- Direct metal laser sintering (DMLS)
- Electron beam fusion (EBM)
- Photopolymerization (SLA, DLP): suitable for anatomical models and surgical guides.

History, Origins: the school in Austin (Texas) and the CO laser

The modern history of 3D printing begins in the 1980s in the United States.

In 1986, Chuck Hull founded 3D Systems and invented stereolithography (SLA), the first patented additive manufacturing process.

Almost simultaneously, at the University of Texas at Austin, Dr. Carl Deckard and Professor Joe Beaman are developing Selective Laser Sintering (SLS), using a CO laser to selectively fuse polymer or metal powders.

This invention, marketed by their company Desk Top Manufacturing (DTM Corp.), laid the foundation for modern metal 3D printing before being integrated into 3D Systems in 2001.

This "school of Austin" has thus transformed the CO laser into an industrial production tool, opening the way to the manufacture of implants and custom medical devices.

Figure 1 CAD / CAM Techology



Figure 2 3D Printing Technology

4. 3D printing technologies applied to orthopaedics

Different technologies coexist according to the materials used and the precision requirements:

- Selective laser sintering (SLS) and selective laser melting (SLM): widely used for metal alloys (titanium, cobalt-chromium, stainless steel, aluminum).
- Direct metal sintering by laser (DMLS): process developed by the German company EOS GmbH, always active and world leader in metal and polymer 3D printing.
- Electron beam fusion (EBM): technology invented by ARCAM AB (Sweden), now part of the GE Additive group, used for medical titanium implants.
- Photopolymerization (SLA, DLP): suitable for producing anatomical models, surgical guides and prototypes.
- Extrusion (FDM, DIW): used for polymers, ceramics and composite materials.

Data from the scanner or medical imaging are transformed into CAD files, then printed layer by layer. This digital chain – scan, modeling, manufacturing – allows for complete customization, essential in modern orthopedic treatment (Fig. 3)

Figure 3 3D Printings in orthopedic treatment

5. Current medical applications

3D printing is today used to manufacture personalized implants and prostheses, perfectly adapted to the anatomy of each patient. The alloys Ti6Al4V, Ti-Nb-Zr and Co-Cr are preferred for their mechanical properties and biocompatibility.

The porous structures obtained by laser fusion promote osteointegration, improving stability without resorting to a bone cement.

- ***The Fraunhofer institutes (ILT, Germany***) are actively pursuing their research on laser processes for implants, in particular on bio-resorbable materials (calcium phosphate, polylactide).
- ***EOS GmbH (Munich)*** continues to be a pioneer in the development of printed vertebral and acetabular implants.
- ***In the United States, ConforMIS Inc***., specialized in custom knee prostheses, has demonstrated equivalent or even superior clinical performances to standard implants; since 2023, the company is part of the restor3d, Inc. group, which pursues these personalized developments.

6. From 3D printing to bio-printing

The next step is three-dimensional bioprinting, which aims to reproduce living biological tissues from human cells and biomaterials.

Three approaches structure this field:

- ***Biomimetics***, which seeks to faithfully reproduce natural cellular and extracellular architectures
- ***Cellular self-assembly***, inspired by the processes of embryonic development
- ***Functional mini-tissues***, modular elements used to reconstruct complete organs. Several industrial and academic actors contribute to this progress.

The companies

- ***L'Oréal and BASF***, in partnership with the start-up Poietis (France, now inactive since 2025), have developed human skin bioprinting processes for cosmetic and medical purposes
- ***The Wallenberg Wood Science Center (Sweden***) demonstrated the feasibility of printing ear cartilage from human cells and biopolymers derived from algae.
- ***Finally, the American company Organovo, now renamed VivoSim Labs Inc***., continues its work on liver and kidney tissues printed for in vitro pharmacological tests.

These advances signal the next step: the production of tissue grafts and, in the longer term, complete organs printed on demand.

7. Outlook to 2025–2030

In the short term (2025-2030), 3D printing will become a standard tool for surgical planning and production of individualized implants.

In the medium term (2030-2050), the convergence between materials engineering, artificial intelligence and bioprinting will pave the way for tailor-made regenerative medicine.

Classical metal implants could be replaced, in some indications, by bio-printed structures integrating stem cells and biodegradable matrices.

The rise of manufacturing on demand will transform the medical supply chain: decentralized production, short circuits and increased sustainability.

This evolution is fully in line with a third industrial revolution, combining digital technologies, biology and medicine.

8. Conclusion-2030

3D printing, and now bio-printing, are redefining the contours of modern orthopaedics.
From the printed metal prosthesis to the bio-fabricated organ, the progress made in less than twenty years is remarkable.
The challenges remain: mastery of micro-architecture, clinical validation, standardization of processes and long-term biological compatibility.
But the dynamic is irreversible: 3D printing is becoming a key pillar of personalized and regenerative medicine in the 21st century.
Horizon 2030: 3D printing will no longer be a technological curiosity, but an integrated ***therapeutic standard*** in surgery and tissue regeneration.

9. Bioprinting in 2050: towards complete regenerative medicine

By 2050, bioprinting should reach a level of technological and clinical maturity that will disrupt the foundations of restorative medicine.
Current advances – today still limited to simple tissues or research prototypes – will evolve towards functional therapeutic applications, based on four main axes:
a)- *Functional and vascularized bio-printed organs*
The joint progress of multicellular bioprinting, microfluidics and bio-inks will create vascularized organs, ensuring internal perfusion and oxygenation.
In 2050, it will be realistic to print partially functional livers, miniaturized kidneys, or even segmental hearts intended to replace defective organs.
These grafts will be printed from the patient's autologous cells, eliminating the risk of immunological rejection and reducing dependence on organ donation.
b- *Hybrid implants: materials + cells*
The integration of metal additive manufacturing and bioprinting processes will lead to a new generation of living hybrid implants.
An orthopedic implant made of titanium or a bio-resorbable alloy can, for example, be covered or infiltrated with osteoblastic cells from the patient, promoting natural and accelerated bone regeneration.
The boundaries between prosthesis and tissue graft will fade: the prosthesis will become an active biological support.
c- *An in situ and automated bioprinting*
The portable, sterile and robotic bioprinters will allow printing directly in the patient's bed or in the operating room.
The first prototypes of this type already exist for skin repair; in 2050, this approach could extend to bone, cartilage and muscle reconstruction after trauma.
The association between intelligent surgical robots and miniaturized bioprinters will allow fully personalized interventions, guided by real-time imaging.
d- *Integrated digital and ethical platforms*
Artificial intelligence and the patient's digital twins will play a central role.
Each printed organ will be preceded by a computer simulation of its morphology, mechanics and integration into the organism.

These virtual models will allow us to test the behavior of the plugin even before its printing.
In parallel, the ethical, regulatory and cell ownership stakes will become crucial: to whom belong the tissues printed from human cells? How to ensure biological safety?

In 2050, bioprinting will no longer be an experimental laboratory, but a major clinical pillar:
• the production of autologous replacement organs;
• personalized tissue repair;
• post-traumatic functional regeneration;
• the radical reduction of the need for classical transplantation.

It will symbolize the fusion of life and digital fabrication, uniting biology, engineering and computing, AI, and Learning Quantum Machine (LQM) in a same therapeutic approach.
Thus, the regenerative medicine of 2050 will probably be printed, connected and biological.

References

1. Hull, C. W. (1986). *Apparatus for production of three-dimensional objects by stereolithography.* U.S. Patent 4575330.
2. Première invention et brevet de la stéréolithographie (SLA), fondant la société 3D Systems.
Deckard, C. R. (1989). *Method and apparatus for producing parts by selective sintering.* U.S. Patent 4863538.
3. Invention du Selective Laser Sintering (SLS) à l'Université du Texas, Austin.
Beaman, J. J., Deckard, C. R., et al. (1992). *Selective Laser Sintering Additive Manufacturing Technology.* University of Texas at Austin.
4. Publication académique fondatrice sur le SLS et l'usage du laser CO_2.
Gibson, I., Rosen, D. W., & Stucker, B. (2015). *Additive Manufacturing Technologies: 3D Printing, Rapid Prototyping, and Direct Digital Manufacturing.* Springer, 2nd ed.
5. Murr, L. E. (2016). *Frontiers of 3D Printing/Additive Manufacturing in Biomaterials, Tissue Engineering, and Organ Printing. Journal of Materials Science & Technology*, 32(10), 987–995.
8.Synthèse des procédés métal et céramique appliqués aux implants médicaux.
9. Berman, B. (2012). *3-D printing: The new industrial revolution. Business Horizons*, 55(2), 155–162.
10. Discussion sur la personnalisation massive et la révolution industrielle associée.
11. Bose, S., Ke, D., Sahasrabudhe, H., & Bandyopadhyay, A. (2018). *Additive manufacturing of biomaterials. Progress in Materials Science*, 93, 45–111.
12.Mavrogenis, A. F., Igoumenou, V. G., et al. (2020). *3D printing of orthopedic implants: clinical experience and future perspectives. Expert Review of Medical Devices*, 17(7), 607–616.
13.Murphy, S. V., & Atala, A. (2014). *3D bioprinting of tissues and organs. Nature Biotechnology*, 32(8), 773–785.
14.Groll, J., Burdick, J. A., Cho, D.-W., et al. (2018). *A definition of bioinks and their distinction from biomaterials. Biofabrication*, 11(1), 013001.
15. Mandrycky, C., Wang, Z., Kim, K., & Kim, D.-H. (2016). *3D bioprinting for engineering complex tissues. Biotechnology Advances*, 34(4), 422–434.
16. Gatenholm, P., et al. (2016). *3D bioprinting of cartilage and soft tissues using nanocellulose bioinks. ACS Biomaterials Science & Engineering*, 2(10), 1705–1713.
17. Organovo Holdings Inc. (2024). *Corporate Research Summary: 3D Human Tissues for Drug Discovery and Regenerative Medicine.* [VivoSim Labs Inc., San Diego].
18.EOS GmbH – *Company Overview and Medical Applications.* (2024). https://www.eos.info/Fraunhofer Institute for Laser Technology ILT – *Additive Manufacturing and Bioprinting Projects.* (2024). https://www.ilt.fraunhofer.de/
19. GE Additive (ex-ARCAM AB) – *Electron Beam Melting Technology Overview.* (2024). https://www.ge.com/additive/
20. restor3d Inc. – *Acquisition of ConforMIS and custom orthopedic implant production.* (Press release, 2023).